Can immune cells predict CART therapy success in myeloma?

NCT ID NCT07180992

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how certain immune cells called monocytes affect the success of CART cell therapy in people with multiple myeloma. Researchers will measure monocyte levels and types before and after treatment in 25 patients. The goal is to find clues that could help predict who will respond best to CART therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which multiple myeloma patients will respond best to CART cell therapy.
What could go wrong: This is a small, early observational study with only 25 participants. It is not testing a new treatment, so it may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CART CELLS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CART CELLS MONOCYTES MULTIPLE MYELOMA

Contacts and locations

Locations

CHRU Amiens
RECRUITING

Amiens, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.